Technical Analysis for HRTX - Heron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 27.03 0.90% 0.24
HRTX closed up 0.9 percent on Friday, January 18, 2019, on 62 percent of normal volume.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical HRTX trend table...

Date Alert Name Type % Chg
Jan 18 Inside Day Range Contraction 0.00%
Jan 17 50 DMA Support Bullish 0.90%
Jan 17 Outside Day Range Expansion 0.90%
Jan 15 Crossed Above 50 DMA Bullish 1.31%
Jan 15 MACD Bullish Centerline Cross Bullish 1.31%
Jan 14 Narrow Range Bar Range Contraction 4.24%
Jan 14 NR7 Range Contraction 4.24%
Jan 14 NR7-2 Range Contraction 4.24%
Jan 11 Narrow Range Bar Range Contraction 3.60%
Jan 11 NR7 Range Contraction 3.60%

Older signals for HRTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Is HRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 16 Heron Therapeutics: Updates To Thesis And PDUFA Date Coming Up
Jan 7 Heron Therapeutics provides 2019 outlook
Jan 7 Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Jan 3 Heron up 3% on positive HTX-011 data
Jan 3 90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
Jan 2 Company News For Jan 2, 2019
Jan 2 Heron Gains on Priority Review Designation for Pain Drug
Jan 2 50 Biggest Movers From Monday
Dec 31 Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 31 Heron stock up 4.3% after opioid alternative granted priority review designation from FDA
See more HRTX news...
Indicators
Indicator Value
52 Week High 42.9
52 Week Low 19.55
Average Volume 971,821
200-Day Moving Average 31.8829
50-Day Moving Average 26.2668
20-Day Moving Average 25.3075
10-Day Moving Average 26.43
Average True Range 1.5041
ADX 13.99
+DI 22.8264
-DI 23.5691
Chandelier Exit (Long, 3 ATRs ) 23.6077
Chandelier Exit (Short, 3 ATRs ) 25.7623
Upper Bollinger Band 28.6207
Lower Bollinger Band 21.9943
Percent B (%b) 0.76
BandWidth 26.183542
MACD Line 0.2537
MACD Signal Line -0.0207
MACD Histogram 0.2744
Fundamentals Value
Market Cap 1.46 Billion
Num Shares 54.1 Million
EPS -4.15
Price-to-Earnings (P/E) Ratio -6.51
Price-to-Sales 59.70
Price-to-Book 11.60
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.49
Resistance 3 (R3) 28.46 27.96 28.24
Resistance 2 (R2) 27.96 27.59 27.97 28.16
Resistance 1 (R1) 27.49 27.36 27.24 27.52 28.08
Pivot Point 26.99 26.99 26.86 27.00 26.99
Support 1 (S1) 26.52 26.62 26.27 26.55 25.98
Support 2 (S2) 26.02 26.39 26.03 25.90
Support 3 (S3) 25.55 26.02 25.82
Support 4 (S4) 25.58